Skip to main content

Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect



CAS Number: 913088-80-9

Therapeutic Category
Central Nervous System (CNS)
API Technology
Dose Form
Oral Solid/Tablets
Dr Reddy's Development Status
Innovator Brand (USA)

Mechanism of Action

Cenobamate is a novel antiepileptic drug that acts as a selective modifier of synaptic transmission. It modulates GABAergic neurotransmission by increasing the GABAergic inhibitory drive on neuronal networks.

The precise mechanism of action of cenobamate is not fully understood, but it is believed to work by increasing the release of the neurotransmitter GABA and enhancing the activation of GABA A receptors, which are the major inhibitory receptors in the central nervous system. This results in an increased inhibition of neurons and a reduction of excitability in the brain, which can help to reduce seizures in patients with epilepsy.

In addition to its effect on GABAergic neurotransmission, cenobamate has been shown to have a low affinity for several other neurotransmitter receptors, including glutamate, dopamine, and norepinephrine receptors. These properties may contribute to the drug's ability to improve seizure control in some patients.

Overall, the mechanism of action of cenobamate is believed to involve a combination of effects on GABAergic neurotransmission and modulation of other neurotransmitter receptors, leading to a reduction in seizures in patients with epilepsy.


Cenobamate is an FDA-approved antiepileptic drug indicated for the treatment of partial-onset seizures in adults with epilepsy.

Partial-onset seizures are a type of seizure that occurs in a specific part of the brain and can cause a variety of symptoms, including motor changes, sensory alterations, and changes in consciousness.

Cenobamate is intended for use as an adjunctive therapy, meaning that it is used in combination with other antiepileptic drugs to improve seizure control in patients who have not achieved adequate control of their seizures with their current treatment.

It is important to note that cenobamate is not a cure for epilepsy and may not work for all patients. The best course of treatment will depend on the individual patient and should be determined by a healthcare professional.

Dr. Reddy's Expertise

Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Cenobamate API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.

Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Cenobamate API is the outcome of the extensive expertise in R&D, IP, and Regulatory.

A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.

Central Nervous System API Products:

Learn More

Contact Us

Please fill in the following form for API Requirement & we'll get back to you shortly

We are here to help, if you have any country specific requirements.


No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.